PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY RRBN Presenter; N Shah; A Alencar; J Gerson; M Patel; W Jurczak; K Patel; A Mato; C Cheah; M Wang;

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY JR Brown; JA Woyach; K Patel; TA Eyre; Cy Cheah; P Ghia; W Jurczak; P Abada; WG Wierda; GFPN Presenter;

SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA R Dalfeor; CS Tam; P Ghia; M Shadman; T Munir; SS Opat; PA Walker; T Tian; J Hirata; JR Brown;